You are correct. They will have to run trials, get reimbursements, etc. No reimbursement payers would pay for additional combo therapy costs until you prove it extends efficacy and quality of life in specific indications.
Therefore all this talk about revenue generation, etc is simply non sense. In fact, I don’t expect any big pharma partnership at all. LP will simply end up diluting shares as she has been doing for the last 10-15 years. An authorized share count increase will be the first step.
Market Data 
Markets 
AI
